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Abstract
Prominin-1 (CD133) is a commonly used cancer stem cell marker in central nervous system (CNS) tumors including
glioblastoma (GBM). Expression of Prom1 in cancer is thought to parallel expression and function in normal stem cells. Using
RNA in situ hybridization and antibody tools capable of detecting multiple isoforms of Prom1, we find evidence for two
distinct Prom1 cell populations in mouse brain. Prom1 RNA is first expressed in stem/progenitor cells of the ventricular zone
in embryonic brain. Conversely, in adult mouse brain Prom1 RNA is low in SVZ/SGZ stem cell zones but high in a rare but
widely distributed cell population (Prom1
hi). Lineage marker analysis reveals Prom1
hi cells are Olig2+Sox2+ glia but Olig1/2
knockout mice lacking oligodendroglia retain Prom1
hi cells. Bromodeoxyuridine labeling identifies Prom1
hi as slow-dividing
distributed progenitors distinct from NG2+Olig2+ oligodendrocyte progenitors. In adult human brain, PROM1 cells are rarely
positive for OLIG2, but express astroglial markers GFAP and SOX2. Variability of PROM1 expression levels in human GBM and
patient-derived xenografts (PDX) – from no expression to strong, uniform expression – highlights that PROM1 may not
always be associated with or restricted to cancer stem cells. TCGA and PDX data show that high expression of PROM1
correlates with poor overall survival. Within proneural subclass tumors, high PROM1 expression correlates inversely with
IDH1 (R132H) mutation. These findings support PROM1 as a tumor cell-intrinsic marker related to GBM survival, independent
of its stem cell properties, and highlight potentially divergent roles for this protein in normal mouse and human glia.
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Introduction
Prominin-1 (Prom1, PROM1, CD133) is a pentaspan trans-
membrane glycoprotein originally identified in immature hema-
topoietic cells [1,2] and now widely regarded as a marker of
normal and cancerous stem cells particularly in the central nervous
system (CNS) [3–7]. In the normal CNS, studies have primarily
focused on characterization of Prom1 in stem cell compartments,
but its expression in other cell types and their lineage is not well
understood. Prominin-1 expression has been reported in oligo-
dendroglia, ependymal cells, and in the human fetal spinal cord [8-
10]. PROM1 cells isolated from the human fetal ventricular zone
have the ability to generate neurospheres, which retain self-
renewal and multi-lineage differentiation capacity [9].
In the adult brain, the distribution and characteristics of
Prominin-1 cells are less well studied. Prom1 expression has been
reported in ependymal cells and murine hippocampus [10,11]. In
transgenic Prom1-lacZ mice, Prom1/lacZ was co-expressed with
Gfap in cells of the subventricular zone (SVZ) having properties of
multi-potent self-renewing neural stem cells. However, Prom1/
lacZ+Gfap- cells single-sorted from this region were not able to
form secondary neurospheres or to differentiate into all neural
lineages. LacZ expression was also noted in cells with non-stem cell
phenotypes widely throughout the adult mouse brain in regions
but whether the endogenous gene is expressed in a similar pattern
was not fully established [5,12].
PROM1 is believed to identify tumor-initiating cancer stem cells
in a wide range of cancer types including leukemia [4], breast [3]
and glioblastoma (GBM), the most common malignant brain
tumor [13]. The cancer stem cell hypothesis suggests that only a
minor subpopulation of the tumor cells maintain tumor growth
and have the indefinite capacity to self-renew. Based on flow
cytometry analysis, PROM1 cells in GBM have been described as
tumor initiating cells able to propagate tumor growth in xenograft
models and confer radioresistance [7,14,15]. However, GBM
PROM1 negative cells can also contribute to tumor propagation
[16,17]. This raises the possibility that PROM1 may not be as
closely linked with ‘‘stemness’’ or tumor initiating phenotype in
normal cells or cancer cells as previously proposed [18].
Recent studies of Prominin-1 expression have used alternatives
to flow cytometry, which allow more direct in situ visualization of
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expression of the multiple complex Prom1 isoforms in mouse and
human. These have also increasingly highlighted its non-stem cell
functions in the hematopoietic, retinal and prostate systems [19–
21]. In addition, expression of Prominin-1 has been reported as
regulated by hypoxia, supporting the possibility that Prominin-1
may be a dynamic marker not necessarily associated with cell
lineage or stemness phenotypes [22]. Considering these findings
we sought to further explore the normal and cancer expression
pattern and lineage associations of Prominin-1 in human and
mouse brain.
Materials and Methods
Animals
Animal husbandry was approved and performed according to
Dana-Farber Cancer Institute’s animal care and use policies. The
Institutional Animal Care and Use Committees of Dana-Farber
Cancer Institute specifically approved protocol 09-016 that
covered all animal procedures.
Lineage analysis
100 Prom1
hi cells were counted for each animal and four
animals were used for each marker analysis. Pictures were taken
on coronal sections of the forebrain from the lateral ventricle to the
hippocampus, with SVZ and corpus callosum included. Results
are presented as the mean calculated between different animals.
BrdU labeling
5-bromodeoxyuridine (BrdU, Sigma) was administered as a
single dose of 50 mg/kg 2 h before euthanasia for short term
labeling or was given once daily for 7 and 14 days for long term
labeling. Two animals were used per time point and about 100
cells expressing BrdU were counted for each area per animal.
Pictures were taken on coronal sections of the forebrain from the
lateral ventricle to the hippocampus, with SVZ and corpus
callosum included.
Stab wound lesion
Stab wound lesions were performed at the following coordinates
(1.5 mm, 3 mm and 2.5 mm). This was repeated 3 times creating
4 stab lesions moving 1.5 mm posterior between each lesion.
Prom1
hi and Olig2 expressing cells were quantified on 10 pictures
(40x). The contra lateral side was used as control. Results are
presented as the mean calculated between different animals; two
animals were used for each time point.
Irradiation
Balb/c mice were given a dose of 3 Gy and sacrificed at 24 h
and 5 d. The number of Prom1
hi cells was determined on coronal
sections of control and irradiated brains from the lateral ventricle
to the hippocampus. Results are presented as the mean calculated
between different animals and two animals were used for each
time point.
Quantitative real time PCR
Specific brain regions were dissected under a dissecting
microscope from 300 um thick fresh vibratome sections, and each
region studied consisted of pooled tissue from 3 mice. Prom1 (Mm
00477115_ml) was analyzed alongside Olig2 (Mm 01210556_ml)
with beta-actin (00607939_sl) as control. This experiment was
done twice.
MACS and FACS
Dissected brain regions were dissociated using Neural Tissue
Dissociation Kit from Miltenyi Biotech. Cell suspensions were
processed using MACS anti-Prominin-1 magnetic micro-beads
(Miltenyi) or Percoll gradient to remove the myelin debris. For
FACS sorting, cell suspensions were incubated with anti-
Prominin-1 PE conjugated antibody 1:20 (Miltenyi, AC133).
Samples were analyzed using BD FACS Aria II.
GBM patient derived cell lines (PDCL)
Patient samples used for this research were collected under two
waived consent protocols, Dana Farber Harvard Cancer Center
protocol #10-043 and Partner’s Human Research Center
protocol #2002 P000995, as well as an informed consent protocol
under Dana Farber Harvard Cancer Center protocol #10-417.
All protocols mentioned have been approved by Dana Farber
Harvard Cancer Center and Partner’s Human Research Center
institutional review boards. Patient derived cell lines were
established from GBM resections, newly diagnosed (n=17) and
recurrent samples (n=5). Tissue was disaggregated using the
gentleMACS Dissociator and enzymatically digested with the
Neural Tissue Dissociation Kit with Papain (Miltenyi). Cells were
plated at a density of 500,000 to 1,000,000 cells in Corning Ultra-
Low attachment cell culture flasks 75 cm
2. Cells were cultured in
neural stem cell media as neurospheres in Stemcell Technologies
NeuroCult NS-A Proliferation Kit (Human) supplemented with
2 ug/ml Heparin, 20 ng/ml human EGF, and 10 ng/ml human
bFGF. Cells were fed weekly by adding fresh media with growth
factors.
GBM patient derived xenografts (PDX)
Cells were dissociated mechanically and 100,000 cells in 1 ul
were injected intra cranially in IcrTac:ICR-Prkdc
SCID mice
(2 mm; 0 mm; 2 mm).
Tissue Fixation
Mice were perfused with 4% paraformaldehyde (PFA) in PBS
(pH 7.0). Brains were post fixed overnight in 4% PFA,
cryoprotected using 0.5 M sucrose/PBS and embedded in OCT
compound (Tissue-Tek). Frozen sections were sectioned at 12 um
(CM1850, Leica) and harvested on superfrost plus glass slides
(Fisher).
RNA In Situ Hybridization (RISH)
Frozen sections were heat treated, 30 min 90uCi n1 0m M
Sodium Citrate buffer pH 6.0 in a steamer, for antigen retrieval.
Sections were pre-hybridized using hybridization buffer followed
by overnight hybridization with digoxigenin (DIG)-UTP-labeled
RNA-probe (1:500 in hybridization buffer). The probe was
synthesized using a DIG labeling kit (Roche). The plasmids
mCD133-pCMV-SPORT6, Open Biosystems; #11776, BC028
286 (mouse PROM1) linearized with Sma1 and hCD133-pOTB7,
hORFeome; MHS1011-76019-4644690, BC012089 (human
PROM1) linearized with BamH1 were used as templates and
transcribed using T7 RNA polymerase to create antisense RNA.
Detection was done with sheep anti-DIG Fab fragments conju-
gated with alkaline phosphatase (Roche). BM Purple (Roche) was
used to visualize bound probe by overnight incubation. For double
labeling by RISH/IHC, sections were stained, as described below,
after the BM purple development step of the RISH (not repeating
antigen retrieval).
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Frozen sections were subjected to antigen retrieval in 10 mM
citrate buffer and blocked using peroxidase-blocking reagent
(DAKO). Primary antibodies were incubated overnight at 4uC,
secondary antibodies were incubated for 2 hours at room temper-
ature and then revealed using horseradish peroxidase-DAB (EnVi-
sion Doublestain Kit, DAKO; K1395). The following antibodies
were used: mouse monoclonal anti-human Prom1/CD133 1:100
(Miltenyi; W6B3C1) expected to recognize the human CD133/1
epitope (same as AC133), rat monoclonal anti-mouse Prom1/
CD133 1:100 (eBioscience; 13A4), rabbit polyclonal anti-mouse/
human Olig2 1:10000 (Chemicon; AB9610), rabbit polyclonal anti-
mouse/human Sox2 1:100 (Chemicon; AB5603), mouse monoclo-
nal anti-mouse/human NeuN 1:100 (Chemicon; MAB377), rabbit
polyclonal anti-mouse/human GFAP 1:2000 (DAKO, Z0334),
mouse monoclonal anti-BrdU 1:100 (BD; 347580), rabbit polyclonal
anti-mouse NG2 1:100 (Chemicon, AB5320).
Immunofluorescence (IF)
Frozen sections were subjected to antigen retrieval in 10 mM
citrate buffer then blocked in 10% goat serum, and incubated with
primary antibody over night at 4uC, washed in TBST, incubated
with secondary antibody and DAPI for 2 h at room temperature.
The following primary antibodies were used: mouse monoclonal
anti-human PROM1/CD133 1:100 (Miltenyi; W6B3C1), rabbit
monoclonal anti-human SOX2 1:1000 (Cell Signaling technolo-
gies; 5024), rabbit polyclonal anti-mouse/human Olig2 1:1000
(Chemicon: AB9610), rabbit polyclonal anti-mouse/human GFAP
1:200 (DAKO; Z0334), rabbit polyclonal anti-human GFAP-Delta
1:500 (Abcam; ab28926), rabbit polyclonal anti-human Ki67
1:1000 (Novocastra; NCL-Ki67p). Secondary antibodies were
anti-mouse Alexa 568 1:1000 (Invitrogen), anti-rabbit FITC 1:100
(Zymed).
Western blot
Tissues were dissected under a dissecting scope from 300 um
thick vibratome sections. Cell lines were pelleted and frozen at 2
80uC. Proteins from tissue and cells were extracted in RIPA buffer
(Boston BioProducts). Equal amounts of protein (20 ug) were
loaded onto the gel (Invitrogen 4–12% Tris-glycine gel). Samples
were transferred, using BioRad semi dry transferring device at
110 V for 1 hour, to Invitrogen Nitrocellulose membrane and
blocked over night at 4uC in 5% milk/PBS. The membrane was
washed in PBST and incubated with primary antibody/PBST for
1 hour. After washing in PBST, the membrane was incubated
with secondary HRP coupled antibody for 1 h at room
temperature and revealed using HyGlo solution (Denville scien-
tific). Antibodies used were rat monoclonal anti-mouse Prom1/
CD133 1:100 (eBioscience; 13A4), for mouse proteins and mouse
monoclonal anti-human PROM1/CD133 1:100 (Miltenyi;
W6B3C1) for human proteins. GAPDH (1:1000, Cell Signaling
Technologies) was used as loading control. Secondary antibodies
were goat anti rat-HRP 1:2000 (Zymed) and rabbit anti Mouse-
HRP 1:2000 (Dako EnVision).
Expression profile analysis
We obtained gene expression profile data from The Cancer
Genome Atlas (TCGA) data [23,24] and PROM1 probe value on
our cohort of cell cultures established from GBM samples was
obtained using HG U133 Plus 2.0 array (Affymetrix) and
presented in table S1. The PROM1 probe is identical in both
array platforms (204304_s_at). For analyses performed we binned
all samples into high (mean value .1000) and low (mean value ,
300) PROM1 expression groups. Fold change of the mean
expression probe value and a p-value was calculated using two-
sided Student’s t-test. The cBioPortal [25,26] was used to analyze
TCGA GBM data regarding PROM1 expression, PDGFRA
aberrations, IDH1 mutation [27] and patient survival [23].
Results
Prom1 RNA is highly expressed in neural stem and
progenitor cell zones in prenatal development
Previous studies of Prom1 expression have been challenging to
interpret due to the fact that many splice variants and modified
forms of Prom1 protein exist, and the exact forms recognized by
different antibodies have not been clearly defined. We therefore
performed an RNA in situ hybridization (RISH) study of mouse
development using a mouse Prom1 probe derived from the open
reading frame (ORF) of the Prom1 gene [28] to detect as many
splice variants as possible.
Prom1 was expressed in all ventricular zone regions of the
central nervous system from E12.5–18.5 (Fig. 1A–a,b). Prom1 was
noted in the ganglionic eminence, hippocampal primordium,
spinal cord and cerebellar ventricular zone and rhombic lip
regions throughout this period. There was little evidence of
significant anatomic or subdomain restriction, although the floor
plate in the spinal cord appeared to maintain high levels of Prom1
up until birth as previously reported [9]. Expression was low to
absent in more differentiated cells adjacent to, or outside the
ventricular zone regions and progressively decreased with time in
all regions. The rapid downregulation of Prom1 in all regions and
cell types suggested that Prom1 expression is highly restricted to
undifferentiated radial glial progenitors and their immediate
progeny during prenatal development.
Dynamic changes in Prom1 expression occur in early
postnatal development
Examination of early postnatal developmental stages showed a
dynamic switch in the Prom1 pattern compared to the prenatal
period. Beginning at P0–P7 high levels of Prom1 were detected
within rare single cells distributed throughout the developing white
matter and cortex (Prom1
hi) (Fig. 1A,c). These cells appeared
distinct from the prenatal Prom1 cells in that expression levels
were higher and the appearance of such cells in each anatomic
region was generally not associated with the maturing stem/
progenitor cell zones. The Prom1
hi cells noted throughout all the
regions of the CNS had the same appearance as those reported
previously in the cerebellar white matter [8]. The Prom1
hi cells did
not appear to represent maintenance of expression within cells
migrating out of the stem cell zones due to much lower expression
in regions immediately adjacent to these zones and their
widespread distribution. Prom1 expression in maturing ventricular
zone regions during P0–P14 progressively declined and was in fact
was extremely low within the specific stem cell niches of the SVZ
and SGZ, where it was expected to be highest based on previous
reports (Fig. 1A c). During this same period several differentiated
cell types appeared by morphology to express low levels of Prom1
including the dentate gyrus granule cell neurons of the
hippocampus, the internal granule cell layer neurons of the
cerebellum, and the ependymal lining of the ventricles (Fig 1A c).
Prom1 is expressed in a rare but widely distributed cell
population in adult mouse brain
The overall expression pattern in adult mouse brain was similar
to that seen in the early postnatal period. The Prom1
hi cells
Prom1 Expression in CNS Development and Gliomas
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entire brain and was considered the predominant cell population
expressing high levels of the gene (Fig. 1B). Prom1
hi cells were
more frequent in white matter tracts than in grey matter regions
(Fig. 1B a,d,e). Low level diffuse Prom1 expression was noted in
the hippocampal marginal layer and cerebellar white matter but
was not apparently associated with Bergmann glia (Fig. 1B c,f).
Occasional Prom1
hi cells were located within or near the SVZ and
SGZ (Fig. 1B a,b,c, arrows) possibly representing overlap with
previously described activated neural stem cells [29] but did not
appear to occur at same frequency expected based on recent
reports [29,30]. Very low diffuse levels of Prom1 were detected in
adult ependymal/subependymal cells (Fig. 1B b), although such
results were variable presumably due to being at the limit of
detection.
To validate the RISH data, we performed qRT-PCR on micro-
dissected regions from vibratome sections of adult mouse brain.
We found that white matter contained more than 3 times higher
levels of Prom1 than grey matter, similar to expression of the
oligodendroglial lineage gene, Olig2 (Fig. 1B g,h,i). Total brain
and dissected sub-regions contained 0.5–2.5 fold more RNA
overall than mouse liver, an organ previously noted to contain low
levels of Prom1 [6].
Given that most prior studies of Prom1 protein did not observe
high levels in white matter regions, we independently evaluated
the presence of Prom1 protein by IHC and Western blot (Fig. S1).
Many Prom1 antibodies are reported to recognize specific
glycosylated antigens (e.g. AC133, CD133) of the Prom1 protein
and we chose to use an antibody that recognizes both glycosylated
and unglycosylated forms of Prom1 (eBioscience; clone 13A4)
[31]. This antibody is expected to recognize all splice forms except
s4 and s5 [6] but would appear to be more restricted compared to
our RNA probes. We noted that Prom1 protein in adult brain was
generally low, but most readily detected in cilia of ependymal cells
lining the lateral ventricle (Fig. S1A). Protein staining in SVZ and
SGZ was generally low relative to ependyma. Interestingly, no
positive cells were detected by IHC in the parenchymal white
matter or grey matter regions that could be regarded analogous to
the Prom1
hi cells detected by RISH. Diffuse weak signal was
sometimes seen in white matter and neuropil regions consistent
with either weak staining or background but was also not
consistently detected (see discussion).
Given the differences in the RISH and IHC staining patterns,
we hypothesized that the protein and its glycosylated or other
forms may not be fully recognized in the IHC analysis. We
therefore performed FACS analysis to determine native Prom1
protein levels. Dissected adult brain regions containing grey matter
(neocortex) or white matter (corpus callosum), were incubated with
Prom1 antibody. Positive and negative fractions were obtained by
MACS and subsequently quantified by FACS. For the white
Figure 1. Prom1 expression in developing and adult mouse CNS. A. RNA in situ hybridization showing high Prom1 expression in the
ventricular zone (vz, arrows) of the prenatal brain and spinal cord (a). Levels decrease over time except in the floor plate (fp). In the cerebellum (b)
Prom1 is highly expressed in the caudal and rostral rhombic lips (rl, cRL, rRL) while postnatal expression is most intense in rare cells of the white
matter (hi, arrows) and the internal granule layer (igl). In postnatal brain (c) expression is conserved at low levels in the stem cell niches (svz and sgz)
but is highest in single cells within white matter (wm, red arrows). B. In adult brain Prom1 RNA is highest in single, widely distributed cells
(arrowheads) in the corpus callosum (a, d), cerebellum (f), gray matter (e) and only rarely in SVZ (b) and the SGZ (c) stem cell niches. Semi-quantitative
RT-PCR of microdissected white and grey matter regions from 3 different mice (g) validate high Prom1 levels in white matter relative to gray matter
and whole brain (p=0.05) (h). Mouse liver acts as a low level reference tissue. The differential level of Prom1 is similar to the oligodendroglial marker
Olig2 (i). ge: ganglionic eminence; ml: molecular layer; gm: grey matter; hp: hippocampus; gcl: granule cell layer; sgz: subgranular zone; cc: corpus
callosum; lv: lateral ventricle; ep: ependymal layer.
doi:10.1371/journal.pone.0106694.g001
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the myelin debris from white matter cells and then performed
FACS directly on the total cell population (MACS was not possible
as an initial enrichment step due to the fibrous and sticky nature of
myelin). Prom1 positive cells comprised 83% of the white matter
cells versus only 22% of the grey matter cells suggesting 4 fold
higher numbers of Prom1 positive cells in white matter, similar to
results for white and grey matter ratios seen with RISH and qRT-
PCR analysis (Fig. S1D, E). To further delineate the pattern of
Prom1 protein, we performed western blot of micro-dissected
regions including grey matter, white matter, ependyma, and SVZ.
Prom1 was detected as a 100 kDa band in every region, with the
highest signal in white matter and low levels in the SVZ/
ependymal layer (Fig. S1B, C). In conclusion, we find that both
Prominin-1 RNA and protein appear to be highest in a widely
distributed cell population in grey and white matter of the adult
mouse brain, with much lower levels in the SVZ/ependymal
regions.
Prom1
hi cells are glial cells with unique properties
To determine the cell lineage of the distributed Prom1
hi cells in
the adult mouse brain, we performed double labeling with Prom1
RISH and IHC for developmental lineage markers (Fig. 2). Nearly
all Prom1
hi cells co-stained with the progenitor cell and
oligodendroglial lineage marker Olig2 in the grey and white
matter (Fig. 2A, C 95–97%). In addition, a subpopulation of
Prom1
hi cells stained positive for the stem cell/astrocyte
transcription factor Sox2 (Fig. 2A, C 11–18%). Only rare weakly
Prom1 positive cells showed possible co-localization with Gfap
(astrocytes, 3–5%), NeuN (neurons, 2%) or NG2 (oligodendroglial
progenitors, 4–5%) (Fig. 2A, C).
Prior studies have suggested that Prom1 is expressed in mature
myelinating oligodendrocytes [32], however the rarity of Prom1
hi
cells and heterogeneity with respect to Sox2 expression observed
here are not typical for myelinating oligodendrocytes or other
known subclasses of oligodendroglia. To address whether Prom1
hi
cells are myelinating oligodendroglia we examined Prom1
expression in Olig1/2 deficient mice in which the entire
oligodendroglial lineage including immature and mature myeli-
nating oligodendroglial cells, fail to develop (Fig. 2B) [33–35].
Surprisingly, at E18.5, the latest stage possible to examine in this
genetic background due to embryonic lethality associated with the
lack of oligodendrocytes, Prom1 expression in the ventricular zone
of knockout mice was retained and appeared identical to controls.
In addition, rare Prom1
hi cells in the fimbria, one of the earliest
white matter tracts to undergo myelination in normal mouse
development, were also unaffected compared to controls (Fig. 2B).
This suggested that Prom1
hi cells are not restricted to mature
myelinating oligodendrocytes but also represent a unique glial cell
type not dependent on Olig gene function.
Prom1
hi cells are slowly-dividing
To evaluate whether Prom1
hi cells might represent a cycling
progenitor cell population and to determine the kinetics of their
turnover, we administrated BrdU to normal adult mice (Fig. 3).
Incorporation of BrdU 2 hours after a single dose, or 7 and 14
days of daily doses was robust within the SVZ region but the rare
Prom1
hi cells in this region were not co-localized with BrdU
(Fig. 3A b, e). In contrast, rare BrdU positive cells co-expressed
Prom1 in grey and white matter regions (,2% of total BrdU cells)
2 hours after a single BrdU administration. Co-labeled cell
number increased following 7 and 14 days of daily BrdU
administration with the percentage of BrdU positive cells
expressing Prom1 being 4 and 20% respectively (Fig. 3A c,f, C).
This slow rate of incorporation in Prom1
hi contrasted with the
finding that by 7 days 68% of BrdU positive cells co-expressed
NG2, a marker of the most abundantly distributed progenitor cell
population in the adult brain (Fig. 3B, C). Moreover, Prom1
hi cells
in grey and white matter (corpus callosum) appeared unaffected by
irradiation suggesting that such cells are radioresistant relative to
the rapidly cycling transit amplifying cells of the SVZ (Fig. S3).
While not fully quantitative, overall these data qualitatively
support that Prom1
hi cells scattered in the white matter and grey
matter are slowly-dividing glial progenitor cells within the adult
mouse brain and appear to be distinct from the more rapidly
dividing larger population of NG2 positive distributed progenitor
cells.
Human Prominin-1 expression and cell lineage
association differ from mouse
Given the differences between mouse and human Prominin-1
structure we sought to more carefully evaluate PROM1 expression
and lineage associations in normal human brain, where its in situ
expression is not well characterized. In human fetal brain (15
weeks estimated gestational age) there was weak PROM1 RNA
expression in the stem/progenitor containing ventricular zone
(VZ) and ependymal regions, most prominently seen in what
appeared to be an interdigitated subependymal cell population. By
immunohistochemistry, PROM1 protein staining was highest in
the microvilli and cilia of ependymal and/or subependymal cells.
Cell bodies of ependymal/subependymal cells were not strongly
stained (Fig. 4A).
To evaluate PROM1 expression in hNSCs distinct from the
ependymal/subependymal cells, we isolated NSC containing
neurospheres from 15 weeks gestational age human fetal brain
ganglionic eminence, and stained the sectioned spheres under
growth conditions for PROM1 RNA and protein. Broad
distribution of the RNA and a more restricted distribution of
protein were noted. Immunofluorescence co-staining of spheres
showed PROM1 co-localized with the glial markers GFAP (95%),
SOX2 (80%), and to a lesser degree OLIG2 (15%). However, the
high percentage of GFAP+ cells in human fetal neural stem cell
cultures may be affected by cell culture conditions given that
endogenous GFAP expression appears somewhat later in devel-
opment in the, 20 to 23 weeks gestation, human ventricular zone
[36,37]. No definitive PROM1+Ki67+ cells could be identified
suggesting PROM1 cells were in a differentiated or a non-
dividing/quiescent stem cell state (Fig. 4A).
In the adult human brain, PROM1 RNA and protein were high
in the ependyma and cilia, similar to prenatal stages (Fig. 4B).
PROM1 RNA and protein were also strongly expressed in cells
with a glial morphology (complex processes by IHC) in the
subependymal astrocyte ribbon and corpus callosum, possibly
representing overlap with recently reported activated SVZ stem
cell subpopulations [29,38]. By immunofluorescence analysis we
noted PROM1 cells in the subependymal astrocytic ribbon co-
expressing the human neural stem cell marker GFAPd [39], but no
significant co-localization with either SOX2 or OLIG2 was
detected in the sub-ventricular zone proper. Rare widely
distributed PROM1 cells were detected in the adult white matter
and subpial zones similar to Prom1
hi cells in the mouse [32].
However, human PROM1
hi cells stained positive for the mature
astrocyte markers GFAP and SOX2 but not OLIG2 (Fig. 4B).
Adult human PROM1 expression therefore differs from mouse
and is predominantly associated with cells having an astrocytic
phenotype.
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Given our findings that PROM1 is expressed in stem as well as
non-stem cells during normal development of mouse and human
we sought to examine whether human GBM PROM1/CD133+
cells might have more similarities to the PROM1
hi cells versus
neural stem cells. To avoid analysis of PROM1 expressing normal
cell types within primary tumors (e.g. vascular and inflammatory
cells) we first examined PROM1 expression in ‘‘pure’’ GBM cell
line models (PDCLs) and xenografts (PDXs).
Immunohistochemical analysis of a panel of 22 patient-derived
GBM cell lines grown in vitro under neural stem cell conditions
(Fig. S4A) showed that 59% of lines (13/22) exhibited very few (,
20% of cells) or no PROM1+ cells and intermediate staining
(positivity in 20–50% of cells) in 18% of the lines (4/22). However
23% of PDCLs (5/22) had expression in nearly all tumor cells (.
90% of tumor cells). These findings were confirmed in a subset of
lines by flow cytometry (Fig. S4B). Similarly, PROM1 levels were
preserved in PDX derived from these same lines (Fig. 5A).
Immunofluorescence studies of PDCLs and PDXs (n=5) revealed
that PROM1 and the proliferation marker KI67 (non-G0 cells)
generally showed only a rare degree of overlap (Fig. 5B and S5).
Analysis of lineage markers showed a pattern similar to normal
PROM1 glial cells with preferential, but not exclusive, expression
Figure 2. Prom1
hi cells are glial cells with novel characteristics. A. Combined RISH:IHC shows single cells with high Prom1 RNA (blue, ISH) co-
localize with oligodendroglial marker Olig2 and astroglial marker Sox2 (brown, IHC) in both white and grey matter. No co-localization was detected
with Gfap, NG2 or NeuN. B. Olig1/2
2/2 knock-out mice (Olig1/2 KO) show Prom1 staining in ventricular zones (arrows) and fimbria white matter
where Prom1
hi cells first emerge (arrows) in E18.5 mouse brain. Olig2+ cells retain protein in Olig1/2 controls (brown, IHC). C. Quantification of the
Prom1 RISH cells co-localizing with lineage markers. cc: corpus callosum; gm: grey matter, wm: white matter; vz: ventricular zone.
doi:10.1371/journal.pone.0106694.g002
Figure 3. Prom1
hi cells are slow dividing distributed progenitor cells distinct from adult NG2 progenitors. A. Two examples of long term
BrdU labeling (7 days, daily dosing) identify rare Prom1+ (RISH; blue) BrdU+ (IHC; brown) cells in white and grey matter (c and f are magnified insets of
the small marked area in a and d). High magnification of the SVZ (b, e) shows numerous BrdU+ stem/progenitor cells that do not express high Prom1.
Arrows indicate rare Prom1
hi+ cells that do not express BrdU (b, e). B. In contrast to Prom1, double IHC for NG2 (brown) and BrdU (red) readily
identifies numerous co-localized cells in SVZ and brain parenchyma. C. Manual quantification of the percentage of BrdU positive cells co-labeled with
Prom1 or NG2 in the white matter, grey matter and SVZ. svz: subventricular zone; lv: lateral ventricle; gm: grey matter; wm: white matter.
doi:10.1371/journal.pone.0106694.g003
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positive GBM cells co-expressed the oligodendroglial marker
OLIG2 (Fig. S5).
PROM1 expression is correlated with shorter survival in
GBM
Prior work suggests that higher PROM1 expression in primary
GBM samples may be associated with poor survival. We examined
the distribution of PROM1 RNA expression across all subclasses
of TCGA samples [23] and our PDCL library, binning patients
into high (.1000 units), medium (300–1000 units), and low (,300
units) groups based on absolute expression values (Fig. S6A, Table
S1). Median patient survival was significantly lower in tumors with
high PROM1 expression compared to those with low expression
in both the TCGA (p=0.0123) and PDCL (p,0.0001) datasets
(Fig. 5D and Fig. S6B).
Absolute PROM1 RNA levels in 171 primary GBM patient
samples from the TCGA showed that the proneural subgroup had
the highest average expression, significantly higher compared to
the mesenchymal subgroup (ANOVA p=0.0239 followed by
Tukey’s multiple comparison test) (Fig. 5C). Moreover, patients
with the highest expression of PROM1 (.1000 units) are
predominantly found in the proneural subclass (12 out of 23).
More in depth analysis of the TCGA proneural subclass showed
that PROM1
low (Z score ,20.5) cases were enriched for IDH1
(R132H) mutation [27]. In contrast, PROM1
high (Z score .2)
cases showed no IDH1 mutations and were enriched for PDGFRA
amplification, which has been associated with poor survival in the
proneural subclass [40] (Fig. 5E and Fig. S6C). In the proneural
group, PROM1
high and PROM1
low samples showed a dramatic
split in the Kaplan-Meier curves where PROM1
high correlates
negatively with overall survival and disease-free survival (Fig. 5F)
and showed no correlation with age (Fig. 5E). This establishes
PROM1 as a tumor cell intrinsic determinant associated with
differential patient survival.
Discussion
Examination of Prominin-1 RNA and protein in vivo across the
entire CNS at embryonic through adult stages fully establishes
Prom1 as a neural stem cell marker present throughout the
Figure 4. PROM1 is expressed in human fetal neural stem cells and in two distinct cell populations in adult human brain. A. PROM1
RNA and protein are highly expressed in ependymal/subependymal cells of the ventricular zone (arrow) particularly in ciliated cells. Images are from
the anterior-lateral germinal matrix/SVZ in the developing cortex. A more heterogeneous expression of PROM1 is detected in neurospheres derived
from human fetal brain (15 gw). Immunofluorescence lineage analysis shows co-localization of PROM1 with SOX2 and GFAP (arrows) but only rare co-
localization with OLIG2 (arrowhead). Co-localization was not detected with proliferating Ki67 positive cells (arrowhead). B. RISH and IHC analysis, on
human adult normal brain tissue shows high PROM1 expression in ependymal cells (arrows) and in cells with glial morphology with complex
processes dispersed within the white and grey matter regions (arrows). PROM1 is present in ependymal cells (ep) and cells within the subependymal
astrocyte ribbon (ar) also positive for GFAPd and SOX2. White and grey matter regions exhibit PROM1 cells with astrocytic morphology that co-
localize with markers SOX2 and GFAP (arrows). PROM1 and OLIG2 co-localization was not detected (arrowhead).
doi:10.1371/journal.pone.0106694.g004
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pattern in these zones during prenatal development is diffuse and
generally not restricted to specific progenitor subdomains known
to exist in these regions [41,42] with the exception of the floor
plate of the neural tube [9]. The absence of staining in early,
intermediate or migrating progenitors suggests that Prom1 is
rapidly down regulated and precisely tied to the differentiation
state of stem cells. This pattern appears to be conserved in the
early human VZ and stem cells cultured from this region, but the
human PROM1 expression pattern was more difficult to
comprehensively assess due to the weak expression and the limited
samples available. Collectively however the pattern suggests
Prominin-1 may have a shared stem cell function in human and
mouse CNS at early embryonic developmental stages.
In the transition from embryonic to perinatal and adult stages of
development we identified a clear and dynamic shift in Prom1
expression. Prior investigations at postnatal time points have
largely focused on expression in stem cell niches or progenitor
zones of the VZ, SVZ, SGZ, and ependyma but rarely describe
Prom1 away from these zones [11,12]. Our studies confirm
expression in progenitor regions and Prom1
hi cells as reported by
others and possibly those cells identified recently as functional stem
cells expressing GFAP and EGFR in a recent study of adult mouse
SVZ [29,30]. Such cells were also possibly identified in the human
Figure 5. High PROM1 expression is associated with IDH1 wild-type, proneural GBM patients with poor survival. A. PROM1 RISH and
IHC show similar patterns of expression in vitro (PDCL; BT216) and in vivo (PDX; BT216). B. Immunofluorescence on BT216 PDCL shows PROM1 co-
localization with GFAP and SOX2 but rarely with proliferative marker Ki67 (arrow). C. PROM1 RNA expression is highest in TCGA proneural subclass,
not statistically significant. PROM1
high cases are found in all 4 groups. D. PROM1 high expression correlated with shorter overall survival in GBM
patients from TCGA. P values using Mantle-Cox. E. cBioPortal analysis of the proneural TCGA subclass shows that PROM1
low correlates with IDH
mutation, while PROM1
high is more associated with PDGFRA amplification. F. Kaplan-Meier analysis of PROM1
high and PROM1
low cases from the TCGA
proneural subclass.
doi:10.1371/journal.pone.0106694.g005
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remarkably low relative to the levels of RNA detected in Prom1
hi
cells of the grey and white matter, unassociated with any stem cell
niches. It is important to note however that discrepancies between
the PROM1 mRNA and protein expression have been reported
before in human colon tissue mostly due to difference in
glycolyslation of CD133 [43]. The non-niche Prom1
hi cells appear
to be identical to cells previously identified as ‘‘lineage null’’ neural
stem cells in the early postnatal cerebellar white matter [8] but
highlights that they are in fact present throughout the entire CNS
at all postnatal and adult stages.
Previous reports suggested that the Prom1
hi cells isolated from
the perinatal (P7) cerebellum could be cultured as multipotent
neural stem cells [8]. However whether such cells might also exist
in adult cerebellum or other regions of the brain has not been
entirely clear. As part of our own investigations, we tested whether
NSC cultures could be isolated from adult Prom1 positive cells by
FACS sorting CD133+ cells from multiple regions of adult mouse
brain, including the cerebellum but were unsuccessful (data not
shown). While technical considerations may explain this result, an
alternate possibility is that cultures in prior studies included a
mixture of Prom1 positive stem/progenitor cells from the SVZ/
VZ rather than being exclusively derived from pure white matter
Prom1
hi cells, an idea supported by recent studies [29]. To this
point, our in vivo BrdU labeling shows that Prom1
hi cells in non-
germinative regions are slow cycling progenitors but mechanical
brain lesioning and irradiation did not appear to stimulate or
ablate Prom1
hi cells as has been described for NSCs in the SVZ
(Fig. S2) [44]. These observations are interesting given that recent
studies in different organ systems (e.g. retina, prostate and
hematopoiesis) have also highlighted the non-stem cell expression
and function of Prominin-1 [19–21]. Our results do not rule out
the possibility that Prom1
hi cells are quiescent non-cycling stem
cells that retain the capability to re-enter the cell cycle and self
renew and in fact such cells have been recently described with
alternative methods and represent an interesting cell type for
future study [29,30].
Our studies and those of others clearly demonstrate that Prom1
is present in multiple glial cell types (ependymal cells, oligoden-
drocytes, and astrocytes) and suggest that significant differences
may exist between mice and humans [45]. Generally CD133
antigen has been less effective as a cancer stem cell marker in mice
than humans, possibly related to the differences we have found in
the cells expressing Prom1. Within species we also noted
differences in the Prom1 cells detected by RNA and protein tools,
most likely due to differential recognition of the many Prom1
splice forms and modifications. While some aspects of the
differences may be due to technical limitations of RNA in situ
hybridization and delayed expression of protein detected by IHC
analysis, the diversity of isoforms and modifications to Prom1
imply that such differences more likely do reflect fundamentally
diverse functions of Prom1. Corbeil et al. describe splice variant 1
(s1) as dominating in the immature brain and variant 3 (s3) as
restricted to postnatal myelinating oligodendrocytes [32]. Al-
though Prom1
hi cells in mouse may be related to the oligoden-
droglial lineage, the retention of such cells in Olig1/2 knock-out
mice, suggests they are not typical oligodendroglial or myelinating
cells. Cycling NG2+Olig2+ adult oligodendrocyte progenitors are
abundant in the adult brain but the lower BrdU labeling in
Prom1
hi cells and lack of co-staining for NG2 distinguishes them
from this population. Further studies and new antibody tools
capable of recognizing diverse forms of Prom1 will be needed to
determine the exact nature of this intriguing Prom1+ cell
population and its relation to other known cell types.
As in the normal brain, our results suggest a reassessment of the
role for PROM1 in CNS cancers beyond that of a highly specific
stem cell marker often assumed in this setting. While PROM1 is
ubiquitously referred to as a marker expressed in only a minor
subpopulation of stem cells in GBM [14], our studies find this is
not consistently the case across different patients. Using TCGA
primary GBM data and PDCL data we did not detect a strong
association of PROM1 with other markers of stem cells when
examined across multiple patients. This included use of methods
for RNA expression profiling, RISH, and IHC. However,
independent of its stem cell associations, PROM1 seems to be
associated with clinically relevant biology in GBM. Multiple
studies have shown neurosphere formation or CD133 antigen
expression to be associated with shorter survival in patients and
mice transplanted with such cells [16,46,47]. Our work with
PROM1 RNA and protein as biomarkers agrees with these
findings. Despite PROM1 having a poor prognostic value as a
cancer stem cell marker, our finding that PROM1 expression is
anti-correlated with IDH1 mutations supports a different biology
for IDH mutant tumors and indicates that PROM1 expression
may be most relevant in the non-IDH mutant setting. Tools for
reliable IHC evaluation of PROM1 in clinical GBM samples are
still lacking, but may be useful for further study of these clinical
associations.
Supporting Information
Figure S1 Prom1+ cells are located in the white matter
and ependymal layer of the adult mouse brain. A.
Immunohistochemical analysis for Prom1 shows weak staining
restricted to ciliated cells in the ependymal layer. B. The different
regions used in the western blot are illustrated in the micrograph.
C. Western blot analysis confirms that Prom1 levels are highest in
white matter and ependymal layer. D. Prom1+ cells isolated from
the mouse cortex analyzed by FACS after MACS sorting show a
moderate level of Prom1 protein. E. FACS sorting for CD133 after
cleanup by Precoll gradient show a high level of Prom1 in the
white matter, which confirmed the RISH staining. cc: corpus
callosum; lv: lateral ventricle; svz: subventricular zone; ep:
ependymal layer; wm: white matter; gm: grey matter; m:
meninges.
(TIF)
Figure S2 Prom1
hi cells in the adult mouse brain do not
proliferate in response to stab wound lesion. A. 7 and 14
days after stab lesion through the cortex and corpus callosum, no
Prom1
hi/BrdU cells are detected around the lesion. B. Quantifi-
cation of the Prom1
hi and Olig2 positive cells around the lesion
show no difference compared to contra lateral side control.
(TIF)
Figure S3 Prom1
hi cells in the corpus callosum exhibit
relative radioresistance. Prom1
hi cells 1 and 5 days after 3 Gy
of irradiation shows no decrease in the Prom1
hi cell population,
while Ki67 proliferative cells are clearly reduced in the
subventricular zone (SVZ).
(TIF)
Figure S4 GBM PDCLs (in vitro) and PDXs (in vivo)
harbor heterogeneous PROM1 patterns. PROM1 immu-
nohistochemistry (A) and FACS (B) on GBM PDCLs and PDXs
identify three distinct groups of PROM1 expression, high, medium
and low/none. In PDCLs with the highest PROM1 levels all cells
express PROM1 homogenously (99% by FACS). PROM1 is
however more heterogeneously expressed in PDCLs with a
Prom1 Expression in CNS Development and Gliomas
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level.
(TIF)
Figure S5 Immunofluorescence analysis from matching
GBM PDX (A) and PDCL (B) (from Figure 5B) shows that
PROM1 cells also stain for stem/glial markers SOX2
and GFAP, few of them being in a proliferative stage,
Ki67 positive.
(TIF)
Figure S6 PROM1 expression is associated with poor
survival and is anti-correlated with IDH1 mutations. A.
PROM1 expression values in TCGA and GBM PDCLs. The
expression value cut offs were arbitrarily designed as followed, ,
300= low, .300 and ,1000= medium, .1000= high. B.
PDXs with high expression of Prom1 have a poor overall survival.
C. Low expression of PROM1 correlates with IDH1 mutation in
the proneural subclass. D. Proneural TCGA cases with high
PROM1 expression do not correlate with age at first diagnosis
(r=0.19).
(TIF)
Table S1 Probe values of Prom1 expression in the GBM
PDCLs.
(XLSX)
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